Related Experiment Video

Updated: Aug 8, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?

M J A de Jonge1, J Verweij

  • 1Dept. Of Medical Oncology, Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. m.dejonge@erasmusmc.nl

European Journal of Cancer (Oxford, England : 1990)
|June 3, 2006
PubMed

Insights

Targeting cancer involves inhibiting multiple signaling pathways. While drug combinations offer dose flexibility, multi-targeted agents simplify treatment. Both strategies face challenges in achieving optimal inhibition within safe toxicity limits.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Receptor tyrosine kinase (RTK) inhibitors are crucial in cancer therapy.
  • Tumor growth and survival often rely on multiple signaling pathways.
  • This necessitates strategies to inhibit these pathways concurrently.

Purpose of the Study:

  • To explore strategies for inhibiting multiple cancer signaling pathways.
  • To compare combination therapy with multi-targeted agents for cancer treatment.
  • To evaluate the feasibility of optimal target inhibition within acceptable toxicity.

Main Methods:

  • Review of strategies involving single-targeted drug combinations.
  • Analysis of multi-targeted agents designed for simultaneous pathway inhibition.
  • Examination of clinical efficacy and toxicity data for approved agents (e.g., BAY 43-9006, SU11248).

Main Results:

  • Combination therapy allows dose titration but poses convenience and drug-interaction issues.
  • Multi-targeted agents simplify treatment regimens.
  • Approved multi-targeted agents show clinical activity, but achieving optimal inhibition at tolerable doses remains a challenge.

Conclusions:

  • Inhibiting multiple cancer signaling pathways is essential for effective treatment.
  • Both combination therapy and multi-targeted agents have advantages and disadvantages.
  • Further research is needed to optimize multi-target inhibition strategies for cancer treatment.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...